Scale-up and intensification of (S)-1-(2-chlorophenyl)ethanol bioproduction: Economic evaluation of whole cell-catalyzed reduction of o-Chloroacetophenone

Biotechnology and Bioengineering

Volumn 110, Issue 8, 2013, Pages 2311-2315

  Eixelsberger, Thomas ^a   Woodley, John M ^b   Nidetzky, Bernd ^a   Kratzer, Regina ^a  

^a GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

(S) 1 (2 chlorophenyl)ethanol; Asymmetric o chloroacetophenone reduction; Biocatalysis intensification and scale up; Candida tenuis xylose reductase; E. coli fermentation; Whole cell bioreduction

Indexed keywords

BIO REDUCTIONS; BIOCATALYST PRODUCTION; CHEMOTHERAPEUTIC DRUGS; E. COLI; ESCHERICHIA COLI CELLS; FORMATE DEHYDROGENASE; SCALE-UP; XYLOSE REDUCTASE;

BIOCONVERSION; CANDIDA; CYTOLOGY; ESCHERICHIA COLI; ETHANOL; EXTRACTION; YEAST;

CELLS;

1 (2 CHLOROPHENYL)ETHANOL; ALCOHOL DERIVATIVE; HEXANE; PHENACYL CHLORIDE; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ALCOHOL PRODUCTION; ARTICLE; BIOCATALYST; BIOREACTOR; BIOTRANSFORMATION; CATALYSIS; CHIRALITY; CONCENTRATION (PARAMETERS); DOWNSTREAM PROCESSING; ECONOMIC EVALUATION; FED BATCH FERMENTATION; NONHUMAN; PH; PRODUCT RECOVERY; SCALE UP; STIRRED REACTOR; TEMPERATURE; WHOLE CELL;

ALCOHOLS; ALDEHYDE REDUCTASE; BIOTECHNOLOGY; BIOTRANSFORMATION; CANDIDA; ESCHERICHIA COLI; FORMATE DEHYDROGENASES; METABOLIC ENGINEERING; OMEGA-CHLOROACETOPHENONE; OXIDATION-REDUCTION; RECOMBINANT PROTEINS;

CANDIDA BOIDINII; CANDIDA TENUIS; ESCHERICHIA COLI;

EID: 84879602199     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24896     Document Type: Article

References (20)

1. Cull SG, Lovick JW, Lye GJ, Angeli P. 2002. Scale-down studies on the hydrodynamics of two-liquid phase biocatalytic reactors. Bioprocess Biosyst Eng 25:143-153.
2. Fricker G, Kromp T, Wendel A, Blume A, Zirkel J, Rebmann H, Setzer C, Martin F, Quinkert RO, Taylor L, Massing U, Müller-Goymann C. 2010. Phospholipids and lipid-based formulations in oral drug delivery. Pharmaceut Res 27:1469-1486.
3. Gröger H, Chamouleau F, Orologas N, Rollmann C, Drauz K, Hummel W, Weckbecker A, May O. 2006. Enantioselective reduction of ketones with "designer cells" at high substrate concentrations: Highly efficient access to functionalized optically active alcohols. Angew Chem Int Ed 45:5677-5681.
4. Gu Y, Shih PH. 2004. Salt-induced phase separation can effectively remove the acetonitrile from the protein sample after the preparative RP-HPLC. Enzym Microb Tech 35:592-597.
5. Hagen AJ, Oliver CN, Sitrin RD. 1997. Optimization and scale-up of solvent extraction in purification of hepatitis A virus (VAQTAT). Biotechnol Bioeng 56:83-88.
6. Junker BH. 2004. Scale-up methodologies for Escherichia coli and yeast fermentation processes. J Biosci Bioeng 7:347-364.
7. Kratzer R, Pukl M, Egger S, Vogl M, Brecker L, Nidetzky B. 2011. Enzyme identification and development of a whole-cell biotransformation for asymmetric reduction of o-chloroacetophenone. Biotechnol Bioeng 108:797-803.
8. Lapidus VL, Donskaya NG, Libinson GS, Tochenaya NP. 1976. Stability in aqueous solutions and acidic properties of carbenicillin. Pharmaceut Chem J 10:810-812.
9. Mädje K, Schmölzer K, Kratzer R, Nidetzky B. 2012. Host cell and expression engineering for development of an E. coli ketoreductase catalyst: Enhancement of formate dehydrogenase activity for regeneration of NADH. Microb Cell Fact 11:1-7.
10. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, Royrre N, Trommeshauser D, Hoesl CE, Munzert G. 2008. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 26:5511-5517.
11. Nagl G. 1999. Optimierung eines fermentationsprozesses zur erzeugung des rekombinanten enzyms mannitol-dehydrogenase in Escherichia coli. PhD thesis, University of Natural Resources and Life Sciences, Vienna. 134 p.
12. Petschacher B, Nidetzky B. 2008. Altering the coenzyme preference of xylose reductase to favor utilization of NADH enhances ethanol yield from xylose in a metabolically engineered strain of Saccharomyces cerevisiae. Microb Cell Fact 7:1-9.
13. Pollard DJ, Woodley JM. 2006. Biocatalysis for pharmaceutical intermediates: The future is now. Trends Biotechnol 25:66-73.
14. Santamaria A, Neef R, Eberspächer U, Eis K, Husemann M, Mumberg D, Prechtl S, Schulze V, Siemeister G, Wortmann L, Barr FA, Nigg EA. 2007. Use of the novel Plk1 inhibitor ZK-Thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis. Mol Biol Cell 18:4024-4036.
15. Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, Tsujino T, Watanabe A, Otsuki S, Mitsuya M, Iida M, Haze K, Machida T, Nakatsuru Y, Komatani H, Kotani H, Iwasawa Y. 2009. Imidazopyridine derivatives as potent and selective polo-like kinase (PLK) inhibitors. Bioorg Med Chem Lett 19:4673-4678.
16. Schmid A, Dordick JS, Hauer B, Kiener A, Wubbolts M, Withold B. 2001. Industrial biocatalysis today and tomorrow. Nature 409:258-268.
17. Schmölzer K, Mädje K, Kratzer R, Nidetzky B. 2012. Process engineering to overcome substrate and product toxicity in E. coli whole cell-catalyzed reduction of o-chloroacetophenone. Bioresour Technol 108:216-223.
18. Tufvesson P, Fu W, Jensen JS, Woodley JM. 2010. Process considerations for the scale-up and implementation of biocatalysis. Food Bioprod Process 88:3-11.
19. Tufvesson P, Lima-Ramos J, Nordblad M, Woodley JM. 2011. Guidelines and cost analysis for catalyst production in biocatalytic processes. Org Proc Res Dev 15:266-274.
20. Von Pawel J, Reck M, Digel W, Kortsik C, Thomas M, Frickhofen N, Schuler M, Gaschler-Markefski B, Hanft G, Sebastian M. 2008. Randomized phase II trial of two dosing schedules of BI 2536, a novel Plk-1 inhibitor, in patients with relapsed advanced or metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol 26:8030.